No. For me it was all side effects with no benefits. I was constantly feeling hypo, I gained 15lbs of water, carpal tunnel, and was so lethargic Id doze off while driving. MK677, and the rest of these RCs like sarms are pure trash and a waste of money. I felt like I was taking poison tbh.
Send it to old Goldie. I’m sure he can use it in the pen.I have one vial of injectable 677 I won in a goldline contest before they got busted again that I've never used because I wasn't sure of it.
Fuck no.Come on guys, tell the truth.... Is running MK-677 almost the same as running 3-5iu of pharm grade HGH??
Do you guys who use it run it yr round?
Thanks in advance
Respect!
B.
I have one vial of *anything* I won in a goldline contest before they got busted again that I've never used because I wasn't sure of it.
Mk has a bad taste to itI've only run DQ's MK677 and Somatozine. DQ's MK tasted like hell and made me lethargic. I like Somatozine in the PM as a sleep aid. Some days my mind will not shut down and that stuff makes me sleep like a baby and gives me crazy vivid dreams.
Thank you Wes for the detailed review. mk is on my radar to runI agree, regular MK677 I have seen in labs that it is consistent with upwards of 2iu of INJ hgh. I prefer HGH over MK677, though I do see MK as a powerful and useful PED. I
I do however have a version of MK677 (not my brand) but I sell it and work for the Brand. MA Labs makes an MK677 blend called Somatozine.
It is mk677 blended with Zinc, vitamin D3, magnesium, selenium, and melatonin. I have seen dozens of clients labs who test levels and are easily equalling 3-4iu of injectable HGH while using it.
"In a fairly recent study, test subjects who were given a 5 mg dose of melatonin experienced a rise in GH levels ranging from 132-157%. One of the mechanisms through which melatonin positively modulates GH release, and which differentiates it from the other ingredients in Somatozine, is its ability to decrease somatostatin levels. As a negative regulator of growth hormone secretion, limiting somatostatin’s influence on somatotrophs (GH producing cells) is an important step in maximizing GH levels. Thankfully for us, a single dose of melatonin was shown to decrease levels of somatostatin by 76-164%. In addition to functioning as a somatostatin inhibitor, melatonin also appears to enhance GH production by increasing the responsiveness of the pituitary gland to growth hormone releasing hormone (GHRH), as evidenced in a 1993 study from “Clinical Endocrinology”.
Melatonin also helps normalize circadian rhythms (i.e. sleep quality), which is in itself an important factor in maximizing GH release, not to mention the massive effect it has on determining our rate of cellular repair (i.e. muscle growth). As cool as this is, melatonin’s ability to improve sleep quality and boost GH levels only tells us part of the story. We must also consider the amount of GH that can actually be used by the body, as not all GH is metabolically active. Luckily for us, melatonin provides assistance in this area by increasing the amount of “free” GH in the bloodstream, indicating a reduction in GHBP’s (growth hormone binding proteins). This was confirmed when researchers found that melatonin positively alters the body’s GH/GHBP-1 ratio (GHBP-1 works to inactivate circulating growth hormone).
Unfortunately, nearly 50% of all GH in circulation is bound to these proteins, essentially rendering it worthless by preventing receptor binding. Since only free GH is biologically, even a small reduction in GHBPs will enhance its positive effects. In this sense, melatonin can be viewed as a type of GH supercharger, allowing us to get more bang for our buck from a given quantity of GH. As a side benefit, melatonin has also been shown to produce a moderate increase in IGFBP-3 levels (6-11%), while also decreasing cortisol levels."
REFERENCES:
https://www.ncbi.nlm.nih.gov/pubmed/25759961
https://www.ncbi.nlm.nih.gov/pubmed/21675994
http://ajcn.nutrition.org/content/81/5/1163.full
https://www.ncbi.nlm.nih.gov/pubmed/23426817
https://www.ncbi.nlm.nih.gov/pubmed/8532589
https://www.ncbi.nlm.nih.gov/pubmed/26595309
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963695/
http://www.mdpi.com/2072-6643/5/10/4184/htm#B93-nutrients-05-04184
http://jn.nutrition.org/content/133/2/442.full
https://www.ncbi.nlm.nih.gov/pubmed/12566481
https://www.ncbi.nlm.nih.gov/pubmed/26631054
https://www.ncbi.nlm.nih.gov/pubmed/8370132
https://www.ncbi.nlm.nih.gov/pubmed/19301769
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174513/
https://www.ncbi.nlm.nih.gov/pubmed/26352863
https://www.ncbi.nlm.nih.gov/pubmed/10548874
http://www.eje-online.org/content/169/6/767.full.pdf
https://www.ncbi.nlm.nih.gov/pubmed/23789983
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289217/
https://www.ncbi.nlm.nih.gov/pubmed/23929734
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319264/
[h=1]Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure[/h]
The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion and body composition in otherwise healthy obese males. The study was randomized, double blind, parallel, and placebo controlled. Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks. Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo). Serum IGF-binding protein-3 was also significantly increased (P < or = 0.001 vs. placebo). GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677. Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment. The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo). Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05). Total and visceral fat were not significantly changed with active therapy. The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1). Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks. We conclude that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3
https://pubmed.ncbi.nlm.nih.gov/9467542/
I agree, regular MK677 I have seen in labs that it is consistent with upwards of 2iu of INJ hgh. I prefer HGH over MK677, though I do see MK as a powerful and useful PED. I
I do however have a version of MK677 (not my brand) but I sell it and work for the Brand. MA Labs makes an MK677 blend called Somatozine.
It is mk677 blended with Zinc, vitamin D3, magnesium, selenium, and melatonin. I have seen dozens of clients labs who test levels and are easily equalling 3-4iu of injectable HGH while using it.
"In a fairly recent study, test subjects who were given a 5 mg dose of melatonin experienced a rise in GH levels ranging from 132-157%. One of the mechanisms through which melatonin positively modulates GH release, and which differentiates it from the other ingredients in Somatozine, is its ability to decrease somatostatin levels. As a negative regulator of growth hormone secretion, limiting somatostatin’s influence on somatotrophs (GH producing cells) is an important step in maximizing GH levels. Thankfully for us, a single dose of melatonin was shown to decrease levels of somatostatin by 76-164%. In addition to functioning as a somatostatin inhibitor, melatonin also appears to enhance GH production by increasing the responsiveness of the pituitary gland to growth hormone releasing hormone (GHRH), as evidenced in a 1993 study from “Clinical Endocrinology”.
Melatonin also helps normalize circadian rhythms (i.e. sleep quality), which is in itself an important factor in maximizing GH release, not to mention the massive effect it has on determining our rate of cellular repair (i.e. muscle growth). As cool as this is, melatonin’s ability to improve sleep quality and boost GH levels only tells us part of the story. We must also consider the amount of GH that can actually be used by the body, as not all GH is metabolically active. Luckily for us, melatonin provides assistance in this area by increasing the amount of “free” GH in the bloodstream, indicating a reduction in GHBP’s (growth hormone binding proteins). This was confirmed when researchers found that melatonin positively alters the body’s GH/GHBP-1 ratio (GHBP-1 works to inactivate circulating growth hormone).
Unfortunately, nearly 50% of all GH in circulation is bound to these proteins, essentially rendering it worthless by preventing receptor binding. Since only free GH is biologically, even a small reduction in GHBPs will enhance its positive effects. In this sense, melatonin can be viewed as a type of GH supercharger, allowing us to get more bang for our buck from a given quantity of GH. As a side benefit, melatonin has also been shown to produce a moderate increase in IGFBP-3 levels (6-11%), while also decreasing cortisol levels."
REFERENCES:
https://www.ncbi.nlm.nih.gov/pubmed/25759961
https://www.ncbi.nlm.nih.gov/pubmed/21675994
http://ajcn.nutrition.org/content/81/5/1163.full
https://www.ncbi.nlm.nih.gov/pubmed/23426817
https://www.ncbi.nlm.nih.gov/pubmed/8532589
https://www.ncbi.nlm.nih.gov/pubmed/26595309
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963695/
http://www.mdpi.com/2072-6643/5/10/4184/htm#B93-nutrients-05-04184
http://jn.nutrition.org/content/133/2/442.full
https://www.ncbi.nlm.nih.gov/pubmed/12566481
https://www.ncbi.nlm.nih.gov/pubmed/26631054
https://www.ncbi.nlm.nih.gov/pubmed/8370132
https://www.ncbi.nlm.nih.gov/pubmed/19301769
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174513/
https://www.ncbi.nlm.nih.gov/pubmed/26352863
https://www.ncbi.nlm.nih.gov/pubmed/10548874
http://www.eje-online.org/content/169/6/767.full.pdf
https://www.ncbi.nlm.nih.gov/pubmed/23789983
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289217/
https://www.ncbi.nlm.nih.gov/pubmed/23929734
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319264/
[h=1]Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure[/h]
The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion and body composition in otherwise healthy obese males. The study was randomized, double blind, parallel, and placebo controlled. Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks. Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo). Serum IGF-binding protein-3 was also significantly increased (P < or = 0.001 vs. placebo). GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677. Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment. The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo). Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05). Total and visceral fat were not significantly changed with active therapy. The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1). Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks. We conclude that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3
https://pubmed.ncbi.nlm.nih.gov/9467542/
I agree, regular MK677 I have seen in labs that it is consistent with upwards of 2iu of INJ hgh. I prefer HGH over MK677, though I do see MK as a powerful and useful PED. I
I do however have a version of MK677 (not my brand) but I sell it and work for the Brand. MA Labs makes an MK677 blend called Somatozine.
It is mk677 blended with Zinc, vitamin D3, magnesium, selenium, and melatonin. I have seen dozens of clients labs who test levels and are easily equalling 3-4iu of injectable HGH while using it.
"In a fairly recent study, test subjects who were given a 5 mg dose of melatonin experienced a rise in GH levels ranging from 132-157%. One of the mechanisms through which melatonin positively modulates GH release, and which differentiates it from the other ingredients in Somatozine, is its ability to decrease somatostatin levels. As a negative regulator of growth hormone secretion, limiting somatostatin’s influence on somatotrophs (GH producing cells) is an important step in maximizing GH levels. Thankfully for us, a single dose of melatonin was shown to decrease levels of somatostatin by 76-164%. In addition to functioning as a somatostatin inhibitor, melatonin also appears to enhance GH production by increasing the responsiveness of the pituitary gland to growth hormone releasing hormone (GHRH), as evidenced in a 1993 study from “Clinical Endocrinology”.
Melatonin also helps normalize circadian rhythms (i.e. sleep quality), which is in itself an important factor in maximizing GH release, not to mention the massive effect it has on determining our rate of cellular repair (i.e. muscle growth). As cool as this is, melatonin’s ability to improve sleep quality and boost GH levels only tells us part of the story. We must also consider the amount of GH that can actually be used by the body, as not all GH is metabolically active. Luckily for us, melatonin provides assistance in this area by increasing the amount of “free” GH in the bloodstream, indicating a reduction in GHBP’s (growth hormone binding proteins). This was confirmed when researchers found that melatonin positively alters the body’s GH/GHBP-1 ratio (GHBP-1 works to inactivate circulating growth hormone).
Unfortunately, nearly 50% of all GH in circulation is bound to these proteins, essentially rendering it worthless by preventing receptor binding. Since only free GH is biologically, even a small reduction in GHBPs will enhance its positive effects. In this sense, melatonin can be viewed as a type of GH supercharger, allowing us to get more bang for our buck from a given quantity of GH. As a side benefit, melatonin has also been shown to produce a moderate increase in IGFBP-3 levels (6-11%), while also decreasing cortisol levels."
REFERENCES:
https://www.ncbi.nlm.nih.gov/pubmed/25759961
https://www.ncbi.nlm.nih.gov/pubmed/21675994
http://ajcn.nutrition.org/content/81/5/1163.full
https://www.ncbi.nlm.nih.gov/pubmed/23426817
https://www.ncbi.nlm.nih.gov/pubmed/8532589
https://www.ncbi.nlm.nih.gov/pubmed/26595309
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963695/
http://www.mdpi.com/2072-6643/5/10/4184/htm#B93-nutrients-05-04184
http://jn.nutrition.org/content/133/2/442.full
https://www.ncbi.nlm.nih.gov/pubmed/12566481
https://www.ncbi.nlm.nih.gov/pubmed/26631054
https://www.ncbi.nlm.nih.gov/pubmed/8370132
https://www.ncbi.nlm.nih.gov/pubmed/19301769
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174513/
https://www.ncbi.nlm.nih.gov/pubmed/26352863
https://www.ncbi.nlm.nih.gov/pubmed/10548874
http://www.eje-online.org/content/169/6/767.full.pdf
https://www.ncbi.nlm.nih.gov/pubmed/23789983
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289217/
https://www.ncbi.nlm.nih.gov/pubmed/23929734
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319264/
[h=1]Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure[/h]
The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion and body composition in otherwise healthy obese males. The study was randomized, double blind, parallel, and placebo controlled. Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks. Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo). Serum IGF-binding protein-3 was also significantly increased (P < or = 0.001 vs. placebo). GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677. Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment. The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo). Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05). Total and visceral fat were not significantly changed with active therapy. The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1). Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks. We conclude that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3
https://pubmed.ncbi.nlm.nih.gov/9467542/
So would there be benefits to taking this in the pm and then gh in the am in a fasted state? Seems like it could lower external gh application and still achieve a desired serum level.
Yes sir there is always a benefit to additional HGH
There is zero question about that. More HGH=More gains in lamens terms
MK677 is a secretagogue and we know it spikes in the body for about 24 hours. Adding Synthetic HGH to that is going to give additional benefits. And additional side effects.
HGH is great in a healthy individual and in say a cancer patient a literal ticking time bomb.
HGH grows all cells. It can grow organs, etc. It can grow bone.
As is additonal HGH, we know from studies puts the individual in a predicament whereas you may experience insane muscle growth and fat loss, etc, etc. But you also may experience issues with insulin, water retention, BP, intestinal and organ growth etc.
So it's impossible for me to say what is optimal.
The 2-3iu of HGH is the most common dosage I have seen in clients in the last 25 years. That's pretty standard, bro science or not.
MK677, believe it or not. I blow alot of peoples minds when I tell them Merck has been studying this since the 90s and it has yet to be approved by the FDA.
But it is close to approval. And if and when it is, you are going to see alot of people stop carrying it.
MK is a beautiful PED. Miraculous in many ways. Its not for everyone. But don't discount any PED. Every PED is a benefit to a bodybuilder whether you prefer it or not.
I agree, regular MK677 I have seen in labs that it is consistent with upwards of 2iu of INJ hgh. I prefer HGH over MK677, though I do see MK as a powerful and useful PED. I
I do however have a version of MK677 (not my brand) but I sell it and work for the Brand. MA Labs makes an MK677 blend called Somatozine.
It is mk677 blended with Zinc, vitamin D3, magnesium, selenium, and melatonin. I have seen dozens of clients labs who test levels and are easily equalling 3-4iu of injectable HGH while using it.
"In a fairly recent study, test subjects who were given a 5 mg dose of melatonin experienced a rise in GH levels ranging from 132-157%. One of the mechanisms through which melatonin positively modulates GH release, and which differentiates it from the other ingredients in Somatozine, is its ability to decrease somatostatin levels. As a negative regulator of growth hormone secretion, limiting somatostatin’s influence on somatotrophs (GH producing cells) is an important step in maximizing GH levels. Thankfully for us, a single dose of melatonin was shown to decrease levels of somatostatin by 76-164%. In addition to functioning as a somatostatin inhibitor, melatonin also appears to enhance GH production by increasing the responsiveness of the pituitary gland to growth hormone releasing hormone (GHRH), as evidenced in a 1993 study from “Clinical Endocrinology”.
Melatonin also helps normalize circadian rhythms (i.e. sleep quality), which is in itself an important factor in maximizing GH release, not to mention the massive effect it has on determining our rate of cellular repair (i.e. muscle growth). As cool as this is, melatonin’s ability to improve sleep quality and boost GH levels only tells us part of the story. We must also consider the amount of GH that can actually be used by the body, as not all GH is metabolically active. Luckily for us, melatonin provides assistance in this area by increasing the amount of “free” GH in the bloodstream, indicating a reduction in GHBP’s (growth hormone binding proteins). This was confirmed when researchers found that melatonin positively alters the body’s GH/GHBP-1 ratio (GHBP-1 works to inactivate circulating growth hormone).
Unfortunately, nearly 50% of all GH in circulation is bound to these proteins, essentially rendering it worthless by preventing receptor binding. Since only free GH is biologically, even a small reduction in GHBPs will enhance its positive effects. In this sense, melatonin can be viewed as a type of GH supercharger, allowing us to get more bang for our buck from a given quantity of GH. As a side benefit, melatonin has also been shown to produce a moderate increase in IGFBP-3 levels (6-11%), while also decreasing cortisol levels."
REFERENCES:
https://www.ncbi.nlm.nih.gov/pubmed/25759961
https://www.ncbi.nlm.nih.gov/pubmed/21675994
http://ajcn.nutrition.org/content/81/5/1163.full
https://www.ncbi.nlm.nih.gov/pubmed/23426817
https://www.ncbi.nlm.nih.gov/pubmed/8532589
https://www.ncbi.nlm.nih.gov/pubmed/26595309
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963695/
http://www.mdpi.com/2072-6643/5/10/4184/htm#B93-nutrients-05-04184
http://jn.nutrition.org/content/133/2/442.full
https://www.ncbi.nlm.nih.gov/pubmed/12566481
https://www.ncbi.nlm.nih.gov/pubmed/26631054
https://www.ncbi.nlm.nih.gov/pubmed/8370132
https://www.ncbi.nlm.nih.gov/pubmed/19301769
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174513/
https://www.ncbi.nlm.nih.gov/pubmed/26352863
https://www.ncbi.nlm.nih.gov/pubmed/10548874
http://www.eje-online.org/content/169/6/767.full.pdf
https://www.ncbi.nlm.nih.gov/pubmed/23789983
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289217/
https://www.ncbi.nlm.nih.gov/pubmed/23929734
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319264/
[h=1]Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure[/h]
The objective of this study was to investigate the effects of oral treatment with the GH secretagogue MK-677 on GH secretion and body composition in otherwise healthy obese males. The study was randomized, double blind, parallel, and placebo controlled. Twenty-four obese males, aged 18-50 yr, with body mass indexes greater than 30 kg/m2 and waist/hip ratios greater than 0.95, were treated with MK-677 25 mg (n = 12) or placebo (n = 12) daily for 8 weeks. Serum insulin-like growth factor I (IGF-I) increased approximately 40% with MK-677 treatment (P < 0.001 vs. placebo). Serum IGF-binding protein-3 was also significantly increased (P < or = 0.001 vs. placebo). GH and PRL (peak and area under the curve values) were significantly increased after the initial dose of MK-677. Significant increases, with the exception of peak PRL, persisted at 2 and 8 weeks of treatment. The increases in GH and PRL after the initial dose were significantly greater than the increase seen after multiple doses. Serum and urinary concentrations of cortisol were not increased at 2 and 8 weeks (P = NS, vs. placebo). Fat-free mass increased significantly in the MK-677 treatment group when determined with dual energy x-ray absorptiometry (P < 0.01) or using a four-compartment model (P < 0.05). Total and visceral fat were not significantly changed with active therapy. The basal metabolic rate was significantly increased at 2 weeks of MK-677 treatment (P = 0.01) but not at 8 weeks (P = 0.1). Fasting concentrations of glucose and insulin were unchanged, whereas an oral glucose tolerance test showed impairment of glucose homeostasis at 2 and 8 weeks. We conclude that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3
https://pubmed.ncbi.nlm.nih.gov/9467542/